Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prourokinase recombinant - Tasly Pharmaceutical

Next Previous
Drug Profile

Prourokinase recombinant - Tasly Pharmaceutical

Alternative Names: B-1140; B-1448; Pro-UK; PUK; Recombinant human pro-urokinase; Recombinant human urokinase - Tasly Pharmaceuticals; rhPro-UK; rhPro-uk - Tasly Pharmaceuticals

Latest Information Update: 24 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tasly Pharmaceuticals, Inc.
  • Class Anti-ischaemics; Plasminogen activator enzymes; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Preregistration Pulmonary embolism
  • Phase III Stroke

Most Recent Events

  • 29 Jan 2023 Tasly Biopharmaceuticals initiates a phase III PROST-2 trial for Stroke in China (IV, Infusion) (NCT05700591)
  • 26 Jan 2023 Tasly Biopharmaceuticals plans a phase III PROST-2 trial for Stroke (IV, Infusion) in February 2023 (NCT05700591)
  • 12 Jul 2022 Preregistration for Pulmonary embolism in China (IV), before July 2022 (Tasly Pharmaceutical pipeline, July 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top